SCHEMBL25822708

SCHEMBL25822708

CC(C)(C)OC(=O)n1cc(-c2ccc3nc(Nc4ccc(N5CCOCC5)cc4)c4nccn4c3c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 11/20 0.47
AURKA O14965 5/20 0.43
FYN P06241 1/20 0.42
SYK P43405 3/20 0.42
CD63 P08962 2/20 0.42
JAK2 O60674 1/20 0.42
NTRK1 P04629 1/20 0.42
ROS1 P08922 1/20 0.42
CSNK2A2 P19784 1/20 0.42
FLT3 P36888 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
BTK Q06187 1/20 0.42
PTK6 Q13882 1/20 0.42
CSNK2A3 Q8NEV1 1/20 0.42
AURKC Q9UQB9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822714 0.88 MAPKAPK5 (0.46) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822675 0.78 MAPKAPK5 (0.67) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822741 0.76 SYK (0.51) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25823182 0.76 SYK (0.49) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822678 0.75 MAPKAPK5 (0.52) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822739 0.75 MAPKAPK5 (0.49) MAPKAPK5
SCHEMBL25822712 0.74 MAPT (0.58) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822737 0.72 MAPKAPK5 (0.42) MAPKAPK5FYNSYKJAK2
SCHEMBL25822681 0.72 MAPKAPK5 (0.67) MAPKAPK5AURKAFYNSYKCD63
SCHEMBL25822683 0.71 MAPKAPK5 (0.54) MAPKAPK5AURKAFYNSYKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 MAPKAPK5 216/4885AURKA 1242/4885FYN 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.